Comparative Pharmacology
Head-to-head clinical analysis: KYPROLIS versus NINLARO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KYPROLIS versus NINLARO.
KYPROLIS vs NINLARO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carfilzomib is an irreversible inhibitor of the proteasome, a large protease complex that degrades ubiquitinated proteins. By blocking proteasome function, carfilzomib disrupts protein homeostasis, leading to accumulation of misfolded proteins, activation of the unfolded protein response, endoplasmic reticulum stress, and ultimately apoptosis, particularly in myeloma cells with high protein turnover.
Ixazomib is a reversible proteasome inhibitor that preferentially binds and inhibits the chymotrypsin-like activity of the 20S proteasome, leading to accumulation of misfolded proteins, induction of apoptosis, and inhibition of cell growth in multiple myeloma cells.
20 mg/m² IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle; increase to 27 mg/m² on day 8 of cycle 1 if tolerated.
4 mg orally once weekly on days 1, 8, and 15 of a 28-day cycle, in combination with lenalidomide and dexamethasone.
None Documented
None Documented
Terminal elimination half-life of 1.3 to 2.1 hours (mean 1.5 hours), supporting continuous infusion scheduling
The terminal elimination half-life of ixazomib is 9.5 days, supporting once-weekly dosing.
Primarily hepatic metabolism; less than 2% of the dose is excreted unchanged in urine and feces combined
Following oral administration of 14C-ixazomib, approximately 80% of the radioactivity is recovered in urine (11% as unchanged drug) and 5% in feces.
Category C
Category C
Proteasome Inhibitor
Proteasome Inhibitor